Sanara MedTech Inc. to Post FY2022 Earnings of ($0.28) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:SMTI)

Sanara MedTech Inc. (NASDAQ:SMTIGet Rating) – Analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for shares of Sanara MedTech in a research report issued on Monday, May 2nd. Cantor Fitzgerald analyst R. Osborn expects that the company will earn ($0.28) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.

Separately, Zacks Investment Research raised shares of Sanara MedTech from a “sell” rating to a “hold” rating in a research note on Wednesday, February 2nd.

Shares of SMTI stock opened at $24.32 on Wednesday. The stock has a 50 day moving average price of $27.01. The company has a market cap of $189.94 million, a P/E ratio of -22.52 and a beta of 2.24. Sanara MedTech has a 12 month low of $18.85 and a 12 month high of $43.89.

Several hedge funds have recently added to or reduced their stakes in SMTI. New York State Common Retirement Fund bought a new stake in shares of Sanara MedTech in the 3rd quarter valued at about $680,000. North Run Capital LP lifted its position in Sanara MedTech by 15.7% in the 4th quarter. North Run Capital LP now owns 65,000 shares of the company’s stock valued at $1,921,000 after acquiring an additional 8,811 shares in the last quarter. Diametric Capital LP boosted its stake in Sanara MedTech by 38.4% in the 4th quarter. Diametric Capital LP now owns 29,362 shares of the company’s stock worth $868,000 after purchasing an additional 8,153 shares during the period. Citadel Advisors LLC acquired a new position in shares of Sanara MedTech during the third quarter worth about $204,000. Finally, Susquehanna International Group LLP raised its position in Sanara MedTech by 30.2% in the 4th quarter. Susquehanna International Group LLP now owns 16,800 shares of the company’s stock valued at $511,000 after buying an additional 3,900 shares during the last quarter. Institutional investors own 4.35% of the company’s stock.

Sanara MedTech Company Profile (Get Rating)

Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution.

Featured Articles

Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.